The booster vaccination of the Moderna vaccine increases the antibody by '83 times', and the preventive effect of the Omicron strain is also confirmed.



With the advent of the Omicron strain of the new coronavirus, which has a large number of mutations, there are voices that threaten the effectiveness of the vaccine. Meanwhile, on December 20, 2021, Moderna released preliminary data that antibodies against the new coronavirus of the Omicron strain increased due to 'booster vaccination' in which an additional vaccine was given.

Moderna announces breaking data on booster vaccination, updates Omicron mutant response strategy | Moderna, Inc. press release
https://prtimes.jp/main/html/rd/p/000000016.000064549.html

Pfizer and BioNTech Provide Update on Omicron Variant | Pfizer
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-omicron-variant

Moderna says booster dose of its COVID-19 vaccine appears protective vs Omicron | Reuters
https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-says-booster-dose-its-covid-19-vaccine-appears-protective-vs-omicron-2021-12-20/

According to Moderna, a blood test of a person who had been vaccinated twice with the new coronavirus vaccine revealed that the level of neutralizing antibody against the Omicron strain was generally low. Therefore, when the modelna vaccine 'mRNA-1273' was boosted at a dose of 50 micrograms, it was confirmed that the antibody titer after 29 days was about 37 times higher than that before the booster vaccination. Furthermore, when a booster infusion of 100 micrograms, which was twice the dose, was performed, the antibody increased by about 83 times that before the booster inoculation. In Japan and the United States, it is recommended to administer 100 micrograms for the second inoculation and 50 micrograms for the third inoculation.

In addition, the content and frequency of adverse events that occurred 7 days after the booster vaccination were almost the same as those of the second vaccination, confirming that the booster vaccination is safe and tolerable. However, the frequency of adverse events tended to be slightly higher with 100 micrograms than with 50 micrograms.

Regarding the results of this study, Moderna CEO Stephane Bancel said, 'The rapid spread of the new coronavirus infection caused by the Omicron strain is now a major concern for the entire world. The data that was able to improve the neutralizing antibody level by about 37 times should be a relief. '



Not only the Moderna vaccine, but also the Pfizer BioNTech vaccine 'BNT162b2' has shown good results in early trials. According to the test results released by Pfizer on December 8, it was confirmed that the neutralizing antibody against the Omicron strain increased 25-fold in the subjects who received the booster of BNT162b2.

Moderna plans to conduct clinical trials of the Omicron strain-specific vaccine 'mRNA-1273.529' in early 2022. In addition, Pfizer and BioNTech have announced that 'Omicron strain-specific vaccines are expected to be available by March 2022.'

Related Posts:

in Science, Posted by log1l_ks